• Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration contractpharma
    April 28, 2021
    ​Samsung Biologics, a contract development and manufacturing organization (CDMO) and TG Therapeutics, are expanding a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.
  • TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial pharmatimes
    April 20, 2021
PharmaSources Customer Service